| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.096 | 0.03 |
| mRNA | XMD15-27 | GDSC1000 | pan-cancer | AAC | -0.073 | 0.03 |
| mRNA | Bryostatin 1 | GDSC1000 | pan-cancer | AAC | -0.074 | 0.03 |
| mRNA | Dasatinib | GDSC1000 | pan-cancer | AAC | -0.1 | 0.03 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.071 | 0.03 |
| mRNA | selumetinib:decitabine (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.069 | 0.03 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | -0.096 | 0.04 |
| mRNA | GDC-0941 | gCSI | pan-cancer | AAC | -0.12 | 0.04 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.067 | 0.04 |
| mRNA | BRD-K51831558 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.04 |